An international collaboration led by scientists at The University of South Australia, SA Pathology in Adelaide, and the de Duve Institute, University of Louvain, Belgium, has discovered biallelic MDFIC pathogenic variants underlying the severe lymphatic disorder, central conducting lymphatic anomaly (CCLA), in seven people from six separate families.
In the February 28, 2022, issue of the Journal of Experimental Medicine, researchers from Washington University in St. Louis have demonstrated that in a mouse model, there is a causal link between murine roseolovirus and autoimmune gastritis.
PERTH, Australia – Prota Therapeutics Ltd.’s lead candidate PRT-120 induced clinical remission of peanut allergy in 51% of children in a phase IIb clinical trial. There are currently no curative therapies to treat food allergies, Prota Therapeutics CEO Mimi Tang told BioWorld. Peanut allergy in children can be particularly problematic because the only treatment is avoidance.
Huadong Medicine Co. Ltd.’s wholly owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has acquired Asia-Pacific rights to two drugs from Kiniksa Pharmaceuticals Ltd. in a deal worth up to $662 million. “This collaboration aims to bring Kiniksa’s therapeutics to patients in the Asia Pacific Region suffering from severe autoimmune and inflammatory diseases,” said Sanj Patel, chairman and CEO of Kiniksa. “The collaboration also provides nondilutive capital, cost-sharing, and resources for clinical trials to accelerate our drug development and commercialization efforts.”
New and updated preclinical and clinical data presented by biopharma firms at the ASCO Genitourinary
Cancers Symposium, including: Amgen, Knopp, Regeneron, Sanofi.
RSS
